Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TK001 in Neovascular Age-Related Macular Degeneration
NCT02613559Phase 1Unknown
- Sponsor
- Jiangsu T-mab Biopharma Co., Ltd.
- Start
- Nov 2015
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label trial of sevacizumab in neovascular age-related macular degeneration (NVAMD) (6 arms), sponsored by Jiangsu T-mab Biopharma Co., Ltd. Primary endpoint: Frequency of ocular and systemic Adverse Events (AEs) and Serious Adverse Events (SAEs) at 6 weeks. Status: unknown.
02
Drugs
sevacizumab
03
Conditions
neovascular age-related macular degeneration (NVAMD)
Beyond the preview
Go deeper on NCT02613559.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02613559.